Wyeth/Solvay bifeprunox hits a snag
This article was originally published in Pharmaceutical Approvals Monthly
Wyeth and Solvay will pursue approval of the atypical antipsychotic bifeprunox for the maintenance of stable adult patients with schizophrenia despite receiving a "not approvable" letter for the drug, Wyeth announces Aug. 10. The companies appear less likely to pursue an indication for the acute treatment of schizophrenia in the near-term, however. "FDA makes it clear that absent a compelling reason, the lower efficacy in the acute use does not support approval," Senior VP Joseph Mahady states during a same-day conference call. The action letter acknowledges the efficacy of bifeprunox in the maintenance setting and outlines a path forward for its approval, which will include completion of a second maintenance study. Approval in that setting could be set back one to two years, the firm said...
You may also be interested in...
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.